Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy

Cancer Journal from Scientific American

Volumn 3, Issue 5, 1997, Pages 289-296

  Khil, Mark S ^a   Kim, Jae Ho ^a   Bricker, Leslie J ^a   Cerny, Joseph C ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Estramustine; Prostrate carcinoma; Radiation therapy

Indexed keywords

ESTRAMUSTINE PHOSPHATE SODIUM; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CARCINOMA CELL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; TUMOR VOLUME; VOMITING;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; ESTRAMUSTINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 0030863991     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kim JH, Leeper R. Treatment of amplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy: a new approach. Cancer 1983;52:954-957.
2. Sordillo P, Magill G, Schauer P. Preliminary trial of combination therapy with Adriamycin and radiation in sarcomas and other malignant tumors. J Surg Oncol 1982;21:23-26.
3. Omura G, Moffit S, Vogler W et al. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980;55:199-204.
4. Byfield J, Barone R, Mendelsohn J. Infusional 5-fluorouracil and X-ray therapy for non-resectable esophageal cancer. Cancer 1980; 45:703-708.
5. Kyriazis A, Yagoda A, Kereiaskes J. Experimental studies on the radiation modifying effect of cis-diammine-dichloro-platinum II (CDP) in human bladder transitional cell carcinomas grown in nude mice. Cancer 1983;52:452-457.
6. Ahlgren J. Estramustine: current status. Semin Oncol 1983;10: 46-47.
7. Tew K, Hartley-Asp B. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology 1984;23:28-33.
8. Kim JH, Khil M, Kim S et al. Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1994;29:555-557.
9. Ryu S, Gabel M, Khil M et al. Estramustine: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 1994;30:99-104.
10. Eklov S, Westlin J, Rikner G et al. Estramustine potentiates the radiation effect in human prostate tumor transplant in nude mice. Prostate 1994;24:39-45.
11. Wang M, Tew K, Stearns M. Immunofluorescent studies of the antimicrotubule effects of the anti-cancer drug estramustine. Anti-canc Res 1983;7:1165-1171.
12. Stearns M, Tew K. Antimicrotubule effect of estramustine, an antiprostatic tumor drug. Cancer Res 1985;45:3891-3897.
13. Stearns M, Tew K. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 1988;89:331-342.
14. Tew K, Stearns M. Estramustine: a nitrogen mustard/steroid with antimicrotubule activity. Pharmacol Ther 1989;43:299-319.
15. Hudes G, Greenberg R, Krigel R et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10:1754-1761.
16. Seidman A, Scher H, Petrylak D. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol 1992;147:931-934.
17. Amato R, Logothetis C, Dexeus F. Preliminary results of phase II trial of estramustine and vinblastine for patients with progressive hormone refractory prostate carcinoma [abstract]. Proceedings of AACR 1991;32:186.
18. Tew K. The mechanism of action of estramustine. Semin Oncol 1983;10:21-26.
19. Hartley-Asp B. Estramustine induced mitotic arrest in two human cell lines, DU-145 and PC-3. Prostate 1984;5:93-100.
20. Gunnarsson P, Forshell G. Clinical pharmacokinetics of estramustine phosphate. Urology 1984;23:22-27.
21. Sheridan V, Speicher L, Tew K. The effects of estramustine on metaphase and anaphase in DU-145 prostatic carcinoma cells. Eur J Cell Biol 1991;54:268-276.
22. Gleason D. Histologic grading and clinical staging of prostate carcinoma. In Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia: Lea & Febiger, 1977;171-197.
23. Lawless J. Statistical Models and Methods for Lifetime Data. New York John Wiley & Sons, 1982.
24. Lee E. Statistical Methods for Survival Data Analysis. Belmont, CA: Lifetime Learning Publications, 1980:129-131, 306-318.
25. Zagars G, Pollack A, von Eschenbach A. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-1380.
26. Zietman A, Coen J, Shipley W et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial PSA value as a predictor of treatment outcome. J Urol 1994;51:640-645.
27. Lee W, Hanks G, Schultheiss T et al. Localized prostate cancer treated by external beam radiotherapy alone: serum prostate-specific antigen driven outcome analysis. J Clin Oncol 1995;13: 464-469.
28. Bagshaw M, Cox R, Ray G. Status of radiation treatment of prostate cancer at Stanford University. Monogr Natl Cancer Inst 1988; 7:47-60.
29. Hanks G, Martz K, Diamond J. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988;15:1299-1305.
30. Perez C, Pilepich M, Zivnuska F. Tumor control in definitive irradiation of localized carcinoma of the prostate. Im J Radiat Oncol Biol Phys 1986;12:523-531.
31. Shipley W, Prout G, Coachman N et al. Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973-1988). Monogr Natl Cancer Inst 1988;7:67-73.
32. Lawton C, Won M, Pilepich M et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991;21:935-936.
33. Smit W, Helle P, Van Putten W et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990;18: 23-29.
34. Schmidt J, Gibbons R, Murphy G et al. Adjuvant therapy for localized prostate cancer. Cancer 1993;71:1005-1013.
35. Zagars G, Johnson D, von Eschenbach A et al. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988;14:1085-1091.
36. Pilepich M, Krall J, al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45: 616-623.
37. Sandberg A. Metabolic aspects and actions unique to Estracyt. Semin Oncol 1983;10:3-15.
38. Bjork P, Forsgren B, Gustavsson J et al. Partial characterization and "quantitation" of human prostatic estramustine binding protein. Cancer Res 1982;42:1935-1942.